Welcome to our dedicated page for Genfit S.A. news (Ticker: GNFT), a resource for investors and traders seeking the latest updates and insights on Genfit S.A. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genfit S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genfit S.A.'s position in the market.
Ipsen has secured global rights to develop and commercialize GENFIT's innovative treatment, elafibranor, aimed at Primary Biliary Cholangitis (PBC). The agreement provides GENFIT with an upfront payment of €120 million and potential milestone payments totaling €360 million, alongside royalties up to 20%. Ipsen will also acquire an 8% equity stake in GENFIT through a €28 million investment. The Phase III trial, ELATIVE™, is ongoing, with top-line data expected in early 2023, presenting a significant opportunity for both companies in addressing unmet medical needs in liver diseases.
FAQ
What is the current stock price of Genfit S.A. (GNFT)?
What is the market cap of Genfit S.A. (GNFT)?
